Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Pivotal trials for PARP inhibitor and ARPI combinations (e.g., PROPEL, MAGNITUDE) enrolled patients who were largely ARPI-naive. However, in modern practice, most patients receive an ARPI earlier in their treatment. This creates significant uncertainty about the benefit of these combinations for the majority of today's patients.
Related Insights
The unselected PROPEL trial showed a broad population benefit, but regulators ultimately restricted its PARP+ARPI approval to BRCA-mutated patients. This aligns with the MAGNITUDE trial, which used prospective selection and halted its non-biomarker arm for futility, validating the necessity of pre-planned genomic stratification.
Data from DUO-E and RUBY Part 2 trials show adding a PARP inhibitor to chemo-immunotherapy provides only a small PFS benefit. Experts are not convinced of its value, citing a lack of overall survival benefit and potential for harm.
The widespread use of PARP inhibitors has altered tumor biology in platinum-sensitive ovarian cancer. A recent meta-analysis of heavily pretreated patients, 97% of whom had prior PARP inhibitor exposure, revealed an objective response rate to subsequent therapy of only 17%—far lower than historical expectations, highlighting a critical unmet clinical need.
The modest benefit of PARP inhibitors in metastatic breast cancer, compared to ovarian cancer, is likely due to resistance induced by prior exposure to DNA-damaging agents like anthracyclines. This explains the clinical rationale for moving PARP inhibitors to earlier treatment settings, such as neoadjuvant or adjuvant therapy, before resistance develops.
The common practice of switching from one ARPI to another upon disease progression is now considered ineffective for most patients. With the advent of proven alternatives like chemotherapy and lutetium, using an "ARPI switch" as the sole control arm in clinical trials is no longer ethically or scientifically sound.
Though cross-trial comparisons are imperfect, Grade 3+ anemia rates offer a stark contrast between approved PARP+ARPI combinations. The rate was 16% for olaparib+abiraterone (PROPEL) versus a much higher 49% for talazoparib+enzalutamide (TALAPRO-2). This suggests toxicity profiles should be a key factor in treatment selection.
Clinical trials combining potent ARPIs like abiraterone and enzalutamide have consistently failed. Once the androgen receptor pathway is maximally suppressed by one agent, adding another with a similar mechanism provides no further clinical advantage, much like hammering a nail that is already flush with the wood.
The BREAKAWAY trial's OS data is from a small, crossover-allowed study, making it hard to interpret alone. However, its findings are believable because they align with and reinforce a "building body of evidence" from larger trials like PROPEL and TALA PRO 2, which also show a survival benefit for PARP inhibitor combinations.
The initial broad enthusiasm for PARP inhibitors in ovarian cancer has been refined. New data confirms a lack of overall survival improvement for patients with HRD-negative (or HR proficient) tumors, pushing clinicians toward a precision medicine approach where these drugs are reserved for patients with BRCA mutations or HRD-positive disease who are most likely to benefit.
Experts advise using PARP inhibitors at the earliest opportunity for patients with BRCA mutations. As prostate cancer advances, it develops additional drivers of disease and intrinsic resistance, which can render targeted therapies like PARP inhibitors less effective if they are reserved for later lines of treatment.
